Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Goldman Sachs analyst Susan Maklari upgraded the rating for Toll Brothers, Inc. (NYSE:TOL) from Sell to Neutral, while raising the price target from $112 to $124. Toll Brothers shares fell 1.2% to close at $119.32 on Friday. See how other analysts view this stock.
- Piper Sandler analyst Edward Tenthoff upgraded Fate Therapeutics, Inc. (NASDAQ:FATE) from Neutral to Overweight and booted the price target from $4 to $6. Fate Therapeutics shares fell 4% to settle at ...